Search

Your search keyword '"Takano-Narazaki, Mariko"' showing total 4 results
Start Over Author "Takano-Narazaki, Mariko" Publisher japanese society of internal medicine
4 results on '"Takano-Narazaki, Mariko"'

1. Immunosuppressive Treatment for an anti-U1 Ribonucleoprotein Antibody-positive Patient with Pulmonary Arterial Hypertension: A Case Report

Author

Matsumoto, Kazuya, primary, Miyawaki, Yoshia, additional, Katsuyama, Takayuki, additional, Nakadoi, Takato, additional, Shidahara, Kenta, additional, Hirose, Kei, additional, Nawachi, Shoichi, additional, Asano, Yosuke, additional, Katayama, Yu, additional, Katsuyama, Eri, additional, Takano-Narazaki, Mariko, additional, Matsumoto, Yoshinori, additional, Mori, Atsushi, additional, Akagi, Satoshi, additional, Sada, Ken-Ei, additional, and Wada, Jun, additional

Published
2023
Full Text
View/download PDF

2. Azathioprine Intolerance in Japanese Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Author

Morishita, Michiko, primary, Watanabe, Haruki, additional, Yan, Minglu, additional, Zeggar, Sonia, additional, Hiramatsu, Sumie, additional, Ohashi, Keiji, additional, Miyawaki, Yoshia, additional, Katsuyama, Eri, additional, Katsuyama, Takayuki, additional, Takano Narazaki, Mariko, additional, Toyota Tatebe, Noriko, additional, Sunahori Watanabe, Katsue, additional, Kawabata, Tomoko, additional, Sada, Ken-Ei, additional, and Wada, Jun, additional

Published
2017
Full Text
View/download PDF

4. Immunosuppressive Treatment for an anti-U 1 Ribonucleoprotein Antibody-positive Patient with Pulmonary Arterial Hypertension.

Author

Matsumoto K, Miyawaki Y, Katsuyama T, Nakadoi T, Shidahara K, Hirose K, Nawachi S, Asano Y, Katayama Y, Katsuyama E, Takano-Narazaki M, Matsumoto Y, Mori A, Akagi S, Sada KE, and Wada J

Subjects
Female, Humans, Adult, Immunosuppressive Agents therapeutic use, Antibodies, Antinuclear, Adrenal Cortex Hormones, Ribonucleoproteins, Pulmonary Arterial Hypertension drug therapy
Abstract

A 34-year-old woman with pulmonary arterial hypertension (PAH) was admitted to the hospital. She had been diagnosed with PAH three years earlier and treated with triple vasodilator therapy. She was positive for anti-U 1 ribonucleoprotein antibodies but did not show any other symptoms associated with autoimmune diseases. Corticosteroid and cyclophosphamide therapy was administered, suspecting the involvement of immunological pathophysiology. After 3 weeks, the mean pulmonary artery pressure decreased from 50 to 38 mmHg without any change in the vasodilators. Immunosuppressive therapy was effective in this patient with PAH with an anti-U 1 ribonucleoprotein-antibody-positive response and might be an option for patients with these specific features.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results